Cue Biopharma, Inc.

NASDAQ:CUE

Biotechnology

Healthcare
$14.10 +1.42%

+$0.38 today

Market cap
$102.43M
Beta
2.53
P/E (TTM)
-6.7
EPS (TTM)
-$4.06
52W Low $4.98High $41.42

Volume 0.21M

Average 0.74M

CUE Debt Repayment

Cash used to repay borrowings during the period.

Cue Biopharma, Inc.NASDAQ: CUE

Debt Repayment · Q1 FY2026 · quarter ended Mar 2026

Debt repayment turns positive

Q1 FY2026 debt repayment was $0, compared with -$1M a year earlier. Trailing-twelve-month debt repayment was -$3.5M.

Context

  • Debt repayment amounted to 16.4% of revenue in FY2025, down 26.7 pp from a year earlier.
  • Debt repayment increased in 0 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly debt repayment holds near $0 or moves back toward the trailing-twelve-month quarterly average of -$875K.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
$0+100.0% QoQ
Last fiscal yearDec 2025
-$4.5M+12.5% YoY
LTMMar 2026
-$3.5M-12.5% YoY
Debt Repayment past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+100.0%——
1 year+12.5%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Debt Repayment history

USD · from the cash flow

Latest · FY2025
(4.5M) USD
Year-over-year change
-12.5%

Debt Repayment vs competitors

How CUE compares with its peers on the latest reported figures

  • CUE's LTM Mar 2026 debt repayment of $3.5M is the 2nd largest of the 7 companies compared; the peer median is $0.
  • Its year-over-year change of -12.5% is the 2nd highest of 5, against a peer median of -81.7%.
  • Debt repayment amounts to 10.7% of revenue for CUE, versus a peer median of 134.6%.
CUE Competitors Peer median
Debt Repayment for CUE and competitors
Company Period LTM YoY 3-year CAGR% of revenue
SPRBSpruce Biosciences, Inc.LTM Mar 2026$14.55M +997.1%——
CUECue Biopharma, Inc.LTM Mar 2026$3.5M -12.5%—10.7%
OTLKOutlook Therapeutics, Inc.LTM Mar 2026$3.23M -1764.2%+9.5%970.3%
NRXPNRx Pharmaceuticals, Inc.LTM Mar 2026$3.09M -63.3%-7.9%134.6%
IPSCCentury Therapeutics, Inc.LTM Mar 2026$0 ———
EQEquillium, Inc.LTM Mar 2026$0 ———
COEPCoeptis Therapeutics, Inc.LTM Mar 2026$0 -100.0%—0.0%
Peer median (excluding CUE) $0-81.7%+0.8%134.6%

Competitors are the stored peer set for CUE. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(44.16M)(53.01M)(50.73M)(40.67M)(26.6M)
Depreciation & Amortization(1.78M)1.81M3.44M2.35M958K
Deferred Income Tax00000
Stock-Based Compensation11.52M9.5M8.18M6.85M4.74M
Change in Working Capital(4.39M)356K(934K)(4.93M)(3.3M)
Accounts Receivables(1.73M)3.09M(1.64M)753K(6.5M)
Inventory00000
Accounts Payables520.4K83K770K(678K)1.13M
Other Working Capital(3.18M)(2.81M)(63K)(5M)2.08M
Other Non-Cash Items(26.13K)(454K)90K74K2.51M
Operating Cash Flow(38.84M)(41.81M)(39.96M)(36.33M)(21.69M)
Capital Expenditures(913.04K)(171K)0(66K)(177K)
Acquisitions (Net)000040K
Purchases of Investments0(29.45M)00(16.5M)
Sales of Investments10M5M25M016.5M
Other Investing Activities21.55K6K2K98K212K
Investing Cash Flow9.11M(24.61M)25M32K75K
Debt Repayment010M(2M)(4M)(4.5M)
Common Stock Issued17.38M39.3M13.39M14.22M30.79M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities1.85M4.36M473K18K0
Financing Cash Flow19.23M53.66M11.86M10.24M26.29M
Effect of Forex Changes00000
Net Change in Cash(10.5M)(12.76M)(3.1M)(26.05M)4.68M
Free Cash Flow(39.75M)(41.98M)(39.96M)(36.4M)(21.86M)

Cue Biopharma, Inc.

NASDAQ:CUE

Intrinsic Alpha fair value

Locked

Current Price

$14.10

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.